Analpram HC Shortage: What Providers and Prescribers Need to Know in 2026

Patients presenting with hemorrhoids, anal fissures, or corticosteroid-responsive dermatoses may receive a prescription for Analpram HC — a combination topical preparation containing hydrocortisone acetate and pramoxine hydrochloride. However, some patients are returning to your practice or calling your office unable to fill this prescription at their local pharmacy.

This clinical brief is designed to help you quickly understand the current availability landscape for Analpram HC in 2026 and equip your team with the information needed to support patients.

Current FDA Shortage Status

As of 2026, Analpram HC is not on the FDA Drug Shortages Database as a nationally declared shortage. The active ingredient combination of hydrocortisone acetate and pramoxine hydrochloride remains commercially available through multiple manufacturers in generic form. That said, brand-name Analpram HC has experienced intermittent regional availability gaps due to factors discussed below.

Regulatory Background: FDA Approval Status

A clinically important consideration: the FDA has not formally approved all formulations of hydrocortisone/pramoxine. Specifically, the 2.5%/1% topical cream formulation (intended for dermatological use) does not carry a formal FDA NDA-approved label. The anorectal/rectal cream formulations (used for hemorrhoids and anorectal conditions) do carry appropriate FDA-cleared labeling.

This distinction matters when prescribing, as some pharmacy benefit managers and insurers scrutinize coverage of formulations without full FDA drug approval. Prescribing for the anorectal indication with the appropriate formulation typically avoids coverage complications.

Why Patients May Have Difficulty Filling Analpram HC

The primary drivers of patient-reported difficulty include:

Low stocking priority: Specialty topical combination products like Analpram HC have lower dispensing volumes than high-frequency drugs, leading pharmacies to stock minimal quantities. A few concurrent prescriptions can deplete local supply.

Brand-name vs. generic confusion: When a prescription specifies Analpram HC by brand name, the pharmacy's system may show it as "out of stock" even if the therapeutically equivalent generic (hydrocortisone-pramoxine topical) is available on-shelf.

Insurance formulary complications: Some formularies place Analpram HC on a non-preferred or non-covered tier, requiring prior authorization or substitution to a generic equivalent. Patients without clear guidance may struggle to navigate this.

Distributor and supply chain gaps: Regional distribution variability can create temporary availability gaps at specific pharmacy chains or geographic areas.

Therapeutic Alternatives: Evidence-Based Options for Your Patients

When Analpram HC cannot be obtained, the following alternatives are clinically appropriate for most indications:

Generic hydrocortisone-pramoxine topical (first choice): Same active ingredients, same strengths (1%/1% or 2.5%/1%). Therapeutically equivalent. More widely stocked; $40–$130 with discount coupon. No DAW required — most prescriptions allow generic substitution.

Pramosone / Proctofoam HC / Epifoam: Brand equivalents containing the same combination; Proctofoam HC and Epifoam offer a foam formulation that some patients prefer for rectal application. Consider when a specific formulation is clinically indicated.

Hydrocortisone/lidocaine combinations (Ana-Lex, Lidamantle HC): Appropriate when pramoxine-specific formulation is unavailable. Note that pramoxine has a structurally unique profile minimizing cross-sensitivity with other amide/ester anesthetics — consider this before switching patients with known local anesthetic sensitivity.

Hydrocortisone rectal suppositories (Anusol-HC, Proctocort): For patients with predominantly internal hemorrhoid symptoms where topical cream application is not preferred.

Rectiv (nitroglycerin 0.4% ointment): Consider when the indication is chronic anal fissure specifically and corticosteroid treatment has been insufficient. Mechanism differs (relaxes internal anal sphincter; promotes fissure healing).

Prescribing Recommendations to Reduce Dispensing Friction

To minimize the chance of a patient being unable to fill their Analpram HC prescription:

Write for the generic (hydrocortisone-pramoxine topical) or use the brand name with DAW-0 (substitution permitted) so the pharmacist can dispense whichever is in stock.

Specify the formulation clearly: cream, lotion, or foam; and the correct strength (1%/1% or 2.5%/1%).

Consider writing a note on the prescription indicating acceptable therapeutic equivalents (e.g., "Pramosone, Proctofoam HC acceptable") to give the pharmacist flexibility.

Proactively inform patients that the generic is therapeutically equivalent and widely available, so they can request it at the pharmacy without needing to contact your office.

How medfinder Helps Your Patients

When patients are unable to locate their medication, the calls often come back to your office — consuming staff time and causing patient frustration. medfinder for providers is a service that helps patients find which pharmacies near them have their prescription in stock. Patients provide the drug name, strength, and location — medfinder calls pharmacies on their behalf and texts them the results. Recommending medfinder to patients reduces callback volume to your office and helps patients get their medications faster.

For a step-by-step patient-facing guide, see: How to Help Your Patients Find Analpram HC in Stock